[4-(1-ethylcarbamoyl-piperidin-4-yloxy)-6-fluoro-naphthalen-2-yl]-acetic acid methyl ester | 1227258-17-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [4-(1-ethylcarbamoyl-piperidin-4-yloxy)-6-fluoro-naphthalen-2-yl]-acetic acid methyl ester
• 英文别名: [4-(1-ethylcarbamoylpiperidin-4-yloxy)-6-fluoronaphthalen-2-yl]acetic acid methyl ester；methyl 2-[4-[1-(ethylcarbamoyl)piperidin-4-yl]oxy-6-fluoronaphthalen-2-yl]acetate
• CAS: 1227258-17-4
• 化学式: C₂₁H₂₅FN₂O₄
• 分子量: 388.439
• InChiKey: RRPCKDGXDYRZOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [6-Fluoro-4-(piperidin-4-yloxy)-naphthalen-2-yl]acetic acid methyl ester 、 异氰酸乙酯 在 乙酸乙酯 、 petroleum ether 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以to afford [4-(1-ethylcarbamoyl-piperidin-4-yloxy)-6-fluoro-naphthalen-2-yl]-acetic acid methyl ester (21.0 mg, 85%) as a viscous oil的产率得到[4-(1-ethylcarbamoyl-piperidin-4-yloxy)-6-fluoro-naphthalen-2-yl]-acetic acid methyl ester
  参考文献：
  名称：

  Naphthylacetic acids

  摘要：

  本发明涉及公式I的化合物及其药学上可接受的盐和酯，其中X，Q和R1-R3在详细说明和权利要求中有定义。本发明还涉及公式Z的化合物及其药学上可接受的盐和酯，其中R1-R3在详细说明和权利要求中有定义。此外，本发明还涉及制造和使用公式I和Z的化合物以及包含这些化合物的制剂的方法。公式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可能在治疗与该受体相关的疾病和障碍，如哮喘方面有用。

  公开号：

  US08188090B2

文献信息

• NAPHTHYLACETIC ACIDS
  申请人：Firooznia Fariborz

  公开号：US20100125061A1

  公开（公告）日：2010-05-20

  The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R 1 -R 3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及公式I的化合物： 以及其药学上可接受的盐和酯，其中X、Q和R1-R3在详细说明和索赔中有定义。该发明还涉及公式Z的化合物： 以及其药学上可接受的盐和酯，其中R1-R3在详细说明和索赔中有定义。此外，本发明涉及制造和使用公式I和Z的化合物的方法，以及含有这些化合物的药物组合物。公式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2358677A1

  公开（公告）日：2011-08-24
• US8188090B2
  申请人：——

  公开号：US8188090B2

  公开（公告）日：2012-05-29
• [EN] NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS<br/>[FR] ACIDES NAPHTYLACÉTIQUES EMPLOYÉS EN TANT QU'ANTAGONISTES OU AGONISTES PARTIELS DE CRTH2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010055006A1

  公开（公告）日：2010-05-20

  The invention is concerned with the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1 -R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.